Marie-Louise, J
Philippakis, E
Darugar, A
Tadayoni, R
Dupas, B
Article History
Received: 14 November 2016
Accepted: 10 April 2017
First Online: 19 May 2017
Competing interests
: EP: Novartis, Bayer, Allergan (travel expenses). RT: board membership (Alcon, Novartis, Allergan, Bausch&Lomb, Pfizer, Alimera, Bayer, FCI-Zeiss, Thrombogenics), consultancy (Alcon, Novartis, Allergan, Bausch&Lomb, Dorc, Takeda, FCI-zeiss, Thrombogenics). BD: consultancy (Novartis, Bayer), board membership (Novartis, Allergan). The remaining authors declare no conflict of interest.